Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

By Rachel Cohrs Zhang, Derek Wallbank, and Hadriana Lowenkron President Donald Trump said he plans to order a cut in US ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Texas grocer H-E-B, along with Kroger, Albertsons and Walgreen Co., is accusing pharmaceutical companies of hurting competition. A recently filed lawsuit alleges Japanese drug maker Takeda ...